Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 2, 1998

View Archived Issues

Diane-35 now available in Canada for treatment of acne

U.S. patent issued for Maxim's MaxVax technology

LIPID study establishes efficacy of pravastatin in patients with lower cholesterol levels

Vical provides clinical update of Leuvectin in treatment of prostate cancer

Mechanism-of-action studies of nifekalant described

Improved antibacterial efficacy observed with OPC-20011

Microbix and Gensia Sicor terminate licensing agreement

Sonus and Daiichi terminate licensing agreement

AMBI seeks partners to develop oral nisin for H. pylori eradication

FDA approves new indications, dosing regimens for Vantin

Health Canada approves lamivudine for treatment of chronic HBV

CPMP issues positive opinion for E.U. approval of Zenapax

Pfizer announces further product launches for novel quinolone

Preclinical study results indicate feasibility of long-term administration of antihypertensive drug

Inhibitors of neovascularization (angiogenesis) patented by JT

Taisho discloses new antitumor series

Gene therapies for neuromuscular diseases pursued by Transgene and AFM

U.K. approval for new controlled-release nifedipine based on TIMERx technology

Albuterol delivered by novel MSI system enters clinical evaluation

Lead SelCID compound poised to enter phase II clinical trials for Crohn's disease

Novel injectable drug delivery technology in-licensed by Medi-Ject

Isis sublicenses technology for designing improved antisense drugs

Additional dose of 5G1.1-SC for phase IIb CPB study identified in phase I trial

Clinical anti-HIV activity of FTC correlated with intracellular levels of triphosphate

Hydroxyurea-containing salvage regimens for advanced-stage HIV infection

Lack of cardiotoxicity of SM-5887 confirmed in dogs

Advisory committee recommends approval of Celebrex for arthritis and further discussions for pain

Comparison of LT and TxA2 antagonists in asthmatic patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...